Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering-Plough Teams Up With Huya To Identify Novel Compounds In China

This article was originally published in PharmAsia News

Executive Summary

Schering-Plough susbsidiary Organon and Huya Bioscience International unveiled an agreement Dec. 15 under which Huya will identify and present to Organon drug candidate compounds originating in China for specific therapeutic areas

You may also be interested in...



U.S.-based Huya Bioscience Signs Drug Development Pact With China's Guangzhou Institutes Of Biomedicine

BEIJING - Huya Bioscience International has signed a partnership agreement with the Guangzhou Institutes of Biomedicine and Health on the joint development of innovative compounds that could provide a bridge between GIBH scientists and the global market, according to Huya's senior leadership

U.S.-based Huya Bioscience Signs Drug Development Pact With China's Guangzhou Institutes Of Biomedicine

BEIJING - Huya Bioscience International has signed a partnership agreement with the Guangzhou Institutes of Biomedicine and Health on the joint development of innovative compounds that could provide a bridge between GIBH scientists and the global market, according to Huya's senior leadership

Fresh Off Schering-Plough Deal, Huya Signs Pact With Beijing Institute To Open Bridge To Global Markets

BEIJING - Huya Bioscience International has signed a partnership agreement with the Beijing Institute of Materia Medica on joint development of innovative drugs that ultimately could help the institute penetrate the American and European markets, according to a senior Huya executive

Latest News
See All
UsernamePublicRestriction

Register

SC067436

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel